Oncological implications of hypoxia inducible factor-1α (HIF-1α) expression

Cancer Treatment Reviews

Volumn 32, Issue 6, 2006, Pages 407-416

  O'Donnell, Jill L ^a   Joyce, Myles R ^b   Shannon, Aoife M ^a   Harmey, Judith ^a   Geraghty, James ^b   Bouchier Hayes, David ^a  

^a BEAUMONT HOSPITAL   (Ireland)

^b ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

Hypoxia; Hypoxia inducible factor 1 ; Transcription factor

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 2 METHOXYESTRADIOL; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; BLEOMYCIN; CELECOXIB; COMPLEMENTARY DNA; DACTINOMYCIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELDANAMYCIN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; IRINOTECAN; PACLITAXEL; PROTEIN KINASE P60; PROTEIN SUBUNIT; RAPAMYCIN; RAS PROTEIN; RECOMBINANT ERYTHROPOIETIN; SMALL INTERFERING RNA; TOPOTECAN; VINCRISTINE;

ADAPTATION; CANCER; CARCINOGENESIS; CELL SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; GENE ACTIVATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HYPOXIA; MALIGNANT TRANSFORMATION; METASTASIS; NONHUMAN; ONCOGENE; PROGNOSIS; PROTEIN EXPRESSION; RADIOSENSITIVITY; REVIEW; SOLID TUMOR; TUMOR RECURRENCE;

ANIMALS; CLINICAL TRIALS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33748152298     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2006.05.003     Document Type: Review

References (112)

1. Bradbury J. Breathing hard to keep up with HIF-1. Lancet 358 (2001) 9294
2. Semenza G.L. HIF-1 and tumour progression: pathophysiology and therapeutics Trends Mol Med 8 Suppl. 4 (2002) S62-S67
3. Wang G.L., Jiang B.H., Rue E.A., and Semenza G.L. Hypoxia inducible factor 1 is a basic loop helix loop PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92 12 (1995) 5510-5514
4. Semenza GL, Wang GL. A nuclear transcription factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation Dec 1992;12(12): 5447-54.
5. Maxwell P.H., Dachs G.U., Gleade J.m., Nichols L.G., Stratford I.J., Hankinson O., et al. Ratcliffe Hyoxia inducible factor 1 modulates geen expression in solid tumours and influences both angiogenesis and tumour growth. Proc Natl Acad Sci USA 94 15 (1997) 8104-8109
6. Jiang B.H., Rue E., Wang G.L., Roe R., and Semenza G.L. Dimerisation, DNA binding anf transactivation properties of hypoxia inducible factor-1. J Biol Chem 271 30 (1996) 17771-17778
7. Jiang B.H., Zheng J.Z., Leung S.W., Roe R., and Semenza G.L. Transactivation and inhibitory domains of hypoxia inducible factor 1α. Modulation of transcriptional activity by oxygen tension. J Biol Chem 272 31 (1997) 19253-19260
8. Huang L.E., Gu J., Schau M., and Bunn H.F. Regulation fo hypoxia inducible factor 1α is mediated by an 02 dependent domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci 95 14 (1998) 7987-7992
9. Mazure N.M., Brahimi-Horn M.C., and Berta M.A. HIF-1: master and commander of the hypoxic world. A pharmacological approach to its regulation by siRNAs. Biochem Pharm 68 (2004) 971-980
10. Goldberg M.A., Dunning S.P., et al. Regulation of erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 242 (1988) 1412-1415
11. Lando D., Peet D.J., Gorman J.J., Whelan D.A., Whitelaw M.L., and Bruick R.K. FIH-1 is an asparginyl hyroxylase enzyme that regulates the transcriptional activity of hypoxia inducible factor. Genes Dev 16 (2002) 1466-1471
12. Hewitson K.S., McNeill L.A., Riordab M.V., Tian Y.M., Bullock A.N., Welford A.W., et al. Hypoxia inducible factor (HIF) asparagines hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem 277 29 (2002) 26351-26355
13. Seeler J.S., and Dejean A. Nuclear and unclear functions of SUMO. Natl Rev Mol Cell Biol 4 9 (2003) 690-699
14. Tojo M., Matsuzaki K., Minami T., Honda Y., Yasuda H., Chiba T., et al. The aryl-hydrocarbon receptor nuclear transporter is modulated by the SUMO-1 conjugation system. J Biol Chem 277 48 (2002) 46576-46585
15. Berta M., Brahimini-Horn C., and Pouyssegur J. Regulation of the Hypoxia Inducible Factor 1α: A breath of fresh air in hypoxia research. J Soc Biol 198 2 (2004) 113-120
16. Jeong J.W., Bae M.K., Ahn M.Y., Kim S.H., Sohn T.K., Bae M.H., et al. Regulation and destabilisation of HIF-1α by ARD-1 mediated acetylation. Cell 111 (2002) 709-720
17. Richard D.E., Berra E., Gothie E., Roux D., and Pouyssegur J. p42/p44 mitogen activated protein kinases phosphorylate hypoxia inducible factor 1α (HIF 1α) and enhance the transcriptional activity of HIF-1. J Biol Chem 274 46 (1999) 32631-32637
18. Suzuki H., Tomida A., and Tsuruo T. Dephosphorylated hypoxia inducible factor 1α as a mediator of p53-dependent apoptosis during hypoxia. Oncogene 20 41 (2001) 5779-5788
19. Sang N., Steihl D.P., Bohensky J., Leshchinsky I., Srinivas V., and Caro J. MAPK signalling up-regulates the activity of hypoxia inducible factors by its effects on p300. J Biol Chem 278 16 (2003) 14013-14019
20. Freedman S.J., Sun Z.Y., Kung A.L., France D.S., Wagner G., and Eck M.J. Structural basis for the negative regulation of hypoxia inducible factor-1α by CITED2. Natl Struct Biol 10 7 (2003) 504-512
21. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
22. Steele R.J.C., Thompson A.M., Hall P.A., and Lane D.P. The p53 tumour suppressor protein. BJS 85 (1998) 1460-1467
23. Graeber T.G., Peterson J.F., Tsai M., Minoca K., Fornace Jr. A.J., and Giaccia A.J.A. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low oxygen conditions is independent of p53 status. Mol cell Biol 14 (1994) 6263-6277
24. Maynard M.A., and Ohh M. Von Hippel Landau tumour suppressor protein and hypoxia inducible factor in kidney cancer. Am J Nephrol 24 1 (2004) 1-13
25. Shi Y.H., Wang Y.X., You J.F., Heng W.J., Zhong H., and Fang W.G. Activation of HIF 1 by bFGF in breast cancer: role of PI-3K and MEK1/ERK pathways. Zhonghua Yi Xue Za Zi 84 22 (2004) 1899-1903
26. Fukuda R., Hirota K., Fan F., Jung Y.D., Ellis L.M., and Semenza G.L. Insulin-like growth factor 1 and induces hypoxia-inducible factor 1 mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidyl 3 kinase signalling in colon cancer cells. J Biol Chem 277 41 (2002) 38205-38211
27. Treins C., Giorgetti-Peraldi S., Murdaca J., Semenza G.L., and Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidyl 3-kinase/target of rapamycin-dependent signalling pathway. J Biol Chem 277 31 (2002) 27975-27981
28. Skinner HD, Zheng JZ, Fang J, Agani F, Jiang BH. Vascular endothelial growth factor transcriptional activity is mediated by hypoxia-inducible factor 1α, HDM2 and p70S6K1 in response to phosphatidyl 3-kinase/AKT signalling.
29. Wu X., Senechal K., Neschat M.S., Whang Y.E., and Sawyers C.l. The PTEN/MMAC1 tumour suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA 95 26 (1998) 15587-15591
30. McMenamin M.E., Soung P., Perera S., Kaplan I., Loda M., and Sellers W.R. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59 17 (1999) 4291-4296
31. Tzahar E., Levkowitz G., Kaunagaran D., Yi L., Peles E., Lavi S., et al. ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms. J Biol Chem 269 40 (1994) 25226-25233
32. Liu W., Li J., and Roth R.A. Heregulin regulation of Akt/protein kinase B in breast cancer cells. Biochem Biophy Res Commun 261 3 (1999) 897-903
33. Bos R., Zhong C., Hanrahan F., Mommers E.C., Semenza G.L., Pinedo H.M., et al. Levels of hypoxia inducible factor 1 during breast carcinogenesis. J Natl Cancer Inst 93 4 (2001) 309-314
34. Bos R., van der Groep P., Greijer A.E., Schvarts A., Meijer S., Pinedo H.M., et al. Levels of hypoxia inducible factor 1α independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97 6 (2003) 1573-1581
35. Laughner E., Taghavi P., Chiles K., Mahon P.C., and Semenza G.L. Her2(neu) signalling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: mechanisms for HIF-1 mediated vascular endothelial growth factor expression. Mol Cell Biol 21 12 (2001) 3995-4004
36. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M., et al. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumour angiogenesis and therapeutics. Cancer Res 60 6 (2000) 1541-1545
37. Hockel M., Vondran B., Schlenger K., Baussman E., and Knapstein P.G. Tumour oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix. Gynaecol Oncol 52 (1993) 141-149
38. Shannon A.M., Bouchier hayes D.J., Condron C.M., and Toomey D. Tumour hypoxia, chemotherapeutic resistance and hypoxia related therapies. Cancer Treat Rev 29 (2003) 297-307
39. Folkmann J., and D'Amore P.A. Blood vessel formation: what is its molecular basis?. Cell 87 7 (1996) 1153-1155
40. Pidgeon G.P., Barr M.P., Harmey J.H., Foley D.A., and Bouchier-Hayes D.J. Vascular endothelial growth factor (VEGF) up-regulates Bcl-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer 85 2 (2001) 272-278
41. Vaupel P., Kallinowski F., and Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumours: a review. Cancer Res 49 23 (1989) 6449-6465
42. Semenza G.L., Jiang B.H., Leung S.W., Passantino R., Concordet J.P., Marie P., et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia inducible factor 1. J Biol Chem 271 51 (1996) 32529-32537
43. Semenza G.L., Roth P.H., Fang H.M., and Wang G.L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia inducible factor 1. J Biol Chem 269 38 (1994) 23757-23763
44. Vaupel P. The role of hypoxia-induced factors in tumour progession. Oncologist 9 Suppl 5 (2004) 1017
45. Moser B., and Loetscher P. Lymphocyte traffic control by chemokines. Natl Immunol 2 2 (2001) 123-128
46. Hall J.M., and Korach K.S. Stromal derived growth factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cell lines. Mol Endocrinol 17 5 (2003) 792-803
47. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 6824 (2001) 50-56
48. Gupta S.K., Lysko P.G., Pillariesetti K., Ohlstein E., and Stadel J.M. Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines. J Biol Chem 273 7 (1998) 4282-4287
49. Samara G.J., Lawrence D.M., Chiarelli C.J., Valentino M.D., Lyubsky S., Zucker S., et al. CXCR4-mediated adhesion and MMP-9 secretion in head and neck squamous cell carcinoma. Cancer Lett 214 (2004) 213-241
50. Hiasa K., Ishibashi M., Ohtani K., Inoue S., Zhao Q., Kitamoto S., et al. Gene transfer of stromal cell-derived factor-1α enhances ischaemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next generation chemokine therapy for therapeutic neo-vascularisation. Circulation 109 25 (2004) 2454-2461
51. Ceradini D.J., Kulkarni A.R., Callaghan M.J., Tepper O.M., Bastidas N., Kleinman M.E., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Natl Med 10 8 (2004) 858-864
52. Stewart S.A., and Weinberg R.A. Telomerase and human tumorigenesis. Semin Cancer Biol 10 6 (2000) 399-406
53. Minamino T., Mitsialis S.A., and Kourembanas S. Hypoxia extends the lifespan of vascular smooth muscle cells through telomerase activation. Mol Cell Biol 21 10 (2001) 3336-3342
54. Nishi H., Nakada T., Kyo S., Inoue M., Shay J.W., and Isaka K. Hypoxia-inducible factor 1 mediates the upregulation of telomerase(hTERT). Mol Cell Biol 24 13 (2004) 6076-6083
55. Holt S.E., Shay J.W., and Wright W.E. Refining the telomere-telomerase hypothesis of aging and cancer. Nat Biotechnol 14 7 (1996) 836-839
56. Zhang P., Chan S.L., Fu W., Mendoza M., and Mattson M.P. TERT suppresses apoptosis at a pre-mitochondrial step by a mechanism requiring reverse transcription activity and 14-3-3 protein binding ability. FASEB J 17 6 (2003) 767-769
57. Kothari s., Cizeau J., McMillan-Ward E., Israels S.J., Bailes M., Ens K., et al. BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene 22 30 (2003) 4734-4744
58. Yasuda M., Han J.W., Dionne C.A., Boyd J.M., and Chinnadurai G. BNIP3alpha: a human homolog of mitochondrial pro-apoptotic protein BNIP3. Cancer Res 59 3 (1999) 533-537
59. Greijer A.E., and van der Wall E. The role of hypoxia inducible factor 1 in hypoxia induced apoptosis. J Clin Pathol 57 10 (2004) 1009-1014
60. Unruh A., Ressel A., Mohamed H.G., Johnson R.S., Nadowitz R., Richter E., et al. The hypoxia inducible factor 1α is a negative factor for tumour therapy. Oncogene 22 21 (2003) 3213-3220
61. Costa A., Coradini D., Carassi A., Erdas R., Sardella A., and Daidone M.G. Re: Levels of hypoxia inducible factor 1α during breast carcinogenesis. J Natl Cancer Inst 93 (2001) 1175-1177
62. Giatromanolaki A., Koukourakis M.I., Sivridis E., Turley H., Tlaks K., Pezella F., et al. Relation of hypoxia inducible factor 1α and 2 alpha in non-operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 85 6 (2001) 881-890
63. Koukourakis M.I., Giatromanolaki A., O'Byrne K.J., Whitehouse R.M., Talbot D.C., Gatter K.C., et al. Potential role of bcl-2 as a suppressor of tumour angiogenesis in non-small cell cancer. Int J Cancer 74 6 (1997) 565-570
64. Gray L.H., Conger A.D., Evert M., et al. The concentration of oxygen in tissues at the time of irradiation as a factor in radiotherapy. Brit J Radiol 26 (1953) 638-648
65. Gray L.H., Cygler J., Klassen N.V., Ross C.K., et al. The survival of aerobic and anoxic human glioma and melanoma cells after irradiation at ultra-high and clinical doses rates. Radiat Res 140 (1994) 79-84
66. Teicher B.A., Lazo J.S., and Sartorelli A.C. Classification of anti-neoplastic agents by their selective toxicities toward oxygenated and hypoxic tumour cells. Cancer Res 41 (1981) 73-81
67. Amellem O., and Peterson E.O. Cell inactivation and cell cycle inhibition as induced by extreme hypoxia: the role of cell cycle arrest as a protection against hypoxia-induced lethal damage. Cell Prolif 244 (1991) 127-141
68. Walker L.J., Craig R.B., Harris A.L., and Hickson I.D. A role for the human DNA repair enzyme HAP1 in cellular protection against DNA damaging agents and hypoxic stress. Nucleic Acids Res 22 (1994) 4884-4889
69. Jain R.K. Normalisation of tumour vasculature: An emerging concept in anti-angiogenic therapy. Science 307 (2005) 58-62
70. Chun Y.S., Choi E., Yeo E.J., Lee J.H., Kin M.S., and Park J.W. A new HIF-1 variant induced by zinc ion suppresses HIF-1 mediated hypoxic responses. J Cell Sci 114 Pt 22 (2001) 4051-4061
71. Chun Y.S., Choi E., Kim T.Y., Kim M.S., and Park J.W. A dominant-negative isoform lacking exons 11 and 12 of the human hypoxia inducible factor 1α gene. Biochem J 362 Pt 1 (2002) 71-79
72. Yeo E.J., Chun Y.S., and Park J.W. New anti-cancer strategies targeting HIF-1. Biochem Pharmacol 68 6 (2004) 1061-1069
73. Hunter T., Hunt T., Jackson R.J., and Robertson H.D. The characteristics of inhibition of protein synthesis by double stranded ribonucleic acid in reticulocyte lysates. J Biol Chem 250 (1975) 409-417
74. Miyagashi M., Hayashi M., and Taira K. Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev 13 (2003) 1-7
75. Mizuno T., Nagao M., Yamada Y., Narikiyo M., Ueno M., Miyagashi M., et al. Small interfering RNA expression vector targeting hypoxia inducible factor-1α inhibits tumour growth in hepatobiliary and pancreatic cancers. Cancer Gene Ther 13 (2006) 131-140
76. Ricker J.L., Chen Z., Yang X.P., Pribluda V.S., Swartz G.M., and Van Waes C. 2 methoxyestradiol inhibits hypoxia inducible factor 1α, tumour growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin Cancer Res 10 24 (2004) 8665-8673
77. Klauber N., Parangi S., Flynn E., Hamel E., and D'amato R.J. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxystrdaiol and taxol. Cancer Res 57 1 (1997) 81-86
78. Ireson C.R., Chander S.K., Purohit A., Perera S., Newma S.P., Parish D., et al. Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyestradiol-bis-sulphunate in vivo in rodents. Br J Cancer 90 4 (2004) 932-937
79. Minet M., Mottet D., Michel G., Roland I., Raes M., Remacle J., et al. Hypoxia induced activation of HIF-1: role of HIF 1α-Hsp90 interaction. FEBS Lett 460 (1999) 251-256
80. Mabjeesh N.J., Post D.E., Willard M.T., Kaur B., Van Meir E.G., Simons J.W., et al. Geldanamycin induces the degradation of hypoxia inducible factor 1α protein via the proteasome pathway in prostate cancer cells. Cancer Res 62 9 (2002) 2478-2482
81. Tulis D.A., Bohl Masters K.S., Lipke E.A., et al. YC-1 mediated vascular protection though inhibition of smooth muscle cell proliferation and platelet function. Biochem Biophys Res Commun 291 (2002) 1014-1021
82. Hsu H.K., Juan S.H., Ho P.Y., Liang Y.C., Lin C.H., Teng C.M., et al. YC-1 inhibits the proliferation of human vascular endothelial cells through a cyclic GMP-independent pathway. Biochem Pharmcol 66 2 (2003) 263-271
83. Wang S.W., Pan S.L., Guh J.H., Chen H.L., Huang D.M., Chang Y.L., et al. YC-1 exhibits a novel anti-proliferative effect and arrests the cell cycle in G0-G1 in human hepatocellular carcinoma cells. J Pharmacol Exp Ther Nov 3 (2004)
84. Ko F.N., Wu C.C., Kuo S.C., Lee F.Y., and Teng C.M. YC-1, a novel activator of platelet guanylate cyclase. Blood 84 (1994) 4226-4233
85. Chun Y.S., Yeo E.J., Choi E., Teng C.M., Bae J.M., Kin M.S., et al. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 61 (2001) 947-954
86. Yeo E.J., Chun Y.S., Cho Y.S., Kim J., Lee J.C., Kim M.S., et al. YC-1: a novel potential anti-cancer drug targeting hypoxia inducible factor 1. J Natl Cancer Inst 5 (2003) 516-525
87. Kamiyama H., Takano S., Tsuboi K., and Matsumura A. Anti-angiogenic effects of SN38(active metabolite of irinotecan): inhibition of hypoxia inducible factor 1α (HIF 1α)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. J Cancer Res Clin Oncol Dec 4 (2004)
88. Krantz S.B. Erythropoietin. Blood 77 (1991) 419-434
89. Jelkmann W. Erythropoietin: structure, control of production and function. Physiol Rev 72 (1992) 449-489
90. Erslev A.J. Erythropoeitin and anemia of cancer. Eur J Haematol 64 (2000) 353-358
91. Becker A., Stadler P., Lavey R.S., Hansgen G., Kuhnt T., Lautenschlager C., et al. Severe anaemia is associated with poor tumour oxygenation in head and neck squamous carcinomas. Int J Radiat Oncol Biol Phys 46 (2000) 459-466
92. Degner F.L., and Sutherland R.M. Mathematical modelling of oxygen supply and oxygenation in tumour tissues: prognostic, therapeutic, and experimental implications. Int J Radiat Oncol Biol Phys 15 (1988) 391-397
93. Silver D.F., and Piver M.S. Effects of recombinant human erythropoietin on the anti-tumour effect of cisplatin in SCID mice bearing human ovarian cancer: A possible oxygen effect. Gynecol Oncol 73 (1999) 280-284
94. Thews O., Koenig R., Kelleher D.K., Kutzner J., and Vaupel P. Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Brit J Cancer 78 (1998) 752-756
95. Thews O., Kelleher D.K., and Vaupel P. Erythropoietin restores the anaemia-induced reduction in cyclophosphamide cytotoxicity in rat tumours. Cancer Res 61 (2001) 1358-1361
96. Sondergaard K.L., Hilton D.A., Penney M., Ollerenshaw M., and Demaine A.G. Expression of hypoxia-inducible factor-1α in tumors of patients with glioblastoma. Neuropathol Appl Neurobiol 28 (2002) 210-217
97. Reardon D.A., Quinn J.A., Vredenburgh J., Rich J.N., Gururangan S., Badruddoja M., et al. Phase 2 trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 103 2 (2005) 329-338
98. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., et al. Role of HIF 1α in hypoxia mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394 6692 (1998) 485-490
99. Huang S., and Houghton P.J. Inhibitors of mammalian target of rapamycin as novel anti-tumour agents: from bench to clinic. Curr Opin Invest Drugs 3 (2002) 295-304
100. Majumder P.K., Febbo P.G., Bikoff R., Berger R., Xue Q., McMahon L.M., et al. mTOR inhibition reverses Akt-dependent prostate intra-epithelial neoplasia through regulation of apoptotic and HIF-1 dependent pathways. Nature Medicine 10 (2004) 594-601
101. Baltaci S., Orhan D., Ozer G., Tolunay O., and Gogous O. Bcl-2 proto-oncogene expression in low and high grade prostatic intra-epithelial neoplasia. BJU Int 85 (2000) 155-159
102. Topotecan. USP DI Drug information for health professional. Update monographs, vol. 1. Englewood, Colorado: Micromedex, Inc.; 2000.
103. Cersosimo R.J. Topotecan: a new topoisomerase 1 inhibiting anti-neoplastic agent. Annals Pharmacother 32 (1998) 1334-1343
104. Michener C.M., and Belinson J.L. Modern management of recurrent ovarian carcinoma. A systematic approach to chronic disease. Oncology (Williston Park) 10 (2005) 1277-1285
105. Huber R.M., Reck M., Gosse H., VonPawel J., Mezger J., Saal J.G., et al. Efficacy of toxicity-adjusted topotecan therapy in recurrent small-cell lung cancer. Eur Respir J Feb 15 (2006)
106. Raza A., Lizak L., Billmeier J., Pervaiz H., Mumtaz M., Gohar S., et al. Phase II trial of topotecan and thalidomide in patients with high risk myelodysplastic syndromes. Leuk Lymphoma 47 (2006) 433-440
107. Beppu K., Nakamura K., Linehan W.M., Rapisarda A., and Thiele C.J. Topotecan blocks hypoxia-inducible factor 1-alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-1 in neuroblastoma cells. Cancer Res 65 (2005) 4775-4781
108. Bernier-Chastagner V., Grill J., Doz F., Bracard S., Gentet J.C., Marie-Cardine A., et al. Topotecan as a radiosensitiser in the treatment of children with malignant diffuse brain-stem glioms: results of a French Society of Pediatric Oncology Phase II study. Cancer 104 (2005) 2792-2797
109. Chintagumpala M.M., Friedman H.S., Stewart C.F., Kepner J., McLendon R.E., Modrich P.L., et al. A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the childrens oncology group. J Neuro-oncol Nov 29 (2005) 1-6
110. Pipas J.M., Meyer L.P., Rhodes C.H., Cromwell L.D., McDonnell C.E., Kingman L.S., et al. A phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytomas. J Neuro-oncol 71 (2005) 301-305
111. Prados M.D., Lamborn K., Yung W.K., Jaeckle K., Robins H.I., Mehta M., et al. A phase 2 trial of irinotecan in patients with recurrent malignant glioma; A North American Brain Tumour Consortium. Neuro-oncol 2 (2006) 183-193
112. Reardon D.A., Quinn J.A., Rich J.N., Desjardins A., Vredenburgh J., Gururangan S., et al. Phase 1 trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer 104 (2005) 1478-1486